Published in J Biol Chem on January 28, 2000
Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A (2001) 2.82
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A (2007) 2.27
Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics (2008) 1.60
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res (2008) 1.54
Expression and importance of matrix metalloproteinase 2 and 9 (MMP-2 and -9) in human trophoblast invasion. Reprod Biol Endocrinol (2004) 1.44
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem (2010) 1.31
TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J (2003) 1.13
TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci Signal (2012) 1.11
Structure of collagenase G reveals a chew-and-digest mechanism of bacterial collagenolysis. Nat Struct Mol Biol (2011) 1.08
Matrix metalloproteinase-9 genotype as a potential genetic marker for abdominal aortic aneurysm. Circ Cardiovasc Genet (2012) 1.05
Classically activated macrophages use stable microtubules for matrix metalloproteinase-9 (MMP-9) secretion. J Biol Chem (2012) 1.04
MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties. J Biol Chem (2007) 1.01
Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod (2013) 0.97
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem (2007) 0.95
Removal of luminal content protects the small intestine during hemorrhagic shock but is not sufficient to prevent lung injury. Physiol Rep (2013) 0.91
Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography. Ann Rheum Dis (2005) 0.91
Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-)catalytic activation and resistance to inhibition by TIMP-1. Biochem J (2007) 0.88
Angiogenic transforming capacity of IgG purified from plasma of type 1 diabetic patients. J Cell Mol Med (2008) 0.87
Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). J Biol Chem (2011) 0.86
Identification and role of the homodimerization interface of the glycosylphosphatidylinositol-anchored membrane type 6 matrix metalloproteinase (MMP25). J Biol Chem (2008) 0.86
Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochem J (2015) 0.84
Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urol (2013) 0.83
Effect of budesonide on fibroblast-mediated collagen gel contraction and degradation. J Inflamm Res (2013) 0.81
Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases. Cancer Biol Ther (2013) 0.81
In vivo perimenstrual activation of progelatinase B (proMMP-9) in the human endometrium and its dependence on stromelysin 1 (MMP-3) ex vivo. Biochem J (2001) 0.81
Dimerization of matrix metalloproteinase-2 (MMP-2): functional implication in MMP-2 activation. J Biol Chem (2012) 0.80
Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9. Reproduction (2010) 0.79
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants. J Cell Mol Med (2014) 0.78
Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors. PLoS One (2012) 0.78
A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5 (ADAMTS-5) Forms Catalytically Active Oligomers. J Biol Chem (2015) 0.77
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization. ACS Med Chem Lett (2017) 0.75
Matrix Metalloproteinase-3 (MMP-3) Is an Endogenous Activator of the MMP-9 Secreted by Placental Leukocytes: Implication in Human Labor. PLoS One (2015) 0.75
Biosynthesis of promatrix metalloproteinase-9/chondroitin sulphate proteoglycan heteromer involves a Rottlerin-sensitive pathway. PLoS One (2011) 0.75
Decreased Homodimerization and Increased TIMP-1 Complexation of Uteroplacental and Uterine Arterial Matrix Metalloproteinase-9 during Hypertension-in-Pregnancy. Biochem Pharmacol (2017) 0.75
Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res (2000) 10.78
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A (1987) 4.83
Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother (1998) 3.37
Matrix metalloproteinases: structures, evolution, and diversification. FASEB J (1998) 2.74
Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother (2000) 2.74
Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience (2001) 2.31
Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases. Proc Natl Acad Sci U S A (2001) 2.21
Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A (1996) 2.12
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res (2001) 2.06
Interindividual concordance of methylation profiles in human genes for tumor necrosis factors alpha and beta. Proc Natl Acad Sci U S A (1990) 2.03
Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol (1993) 2.01
Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci U S A (1998) 1.97
Elucidation of the role of arginine-244 in the turnover processes of class A beta-lactamases. Biochemistry (1992) 1.96
The 5-HT(1A) receptor knockout mouse and anxiety. Behav Pharmacol (2001) 1.85
Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure (2000) 1.84
Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem (1997) 1.81
The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience (2003) 1.69
Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet (1997) 1.69
Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res (1995) 1.63
Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry (1994) 1.63
Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem (2000) 1.59
How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. Adv Exp Med Biol (1998) 1.58
Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc Natl Acad Sci U S A (1999) 1.56
Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res (1999) 1.56
Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem (2001) 1.54
A structure-based analysis of the inhibition of class A beta-lactamases by sulbactam. Biochemistry (1994) 1.47
A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A (2001) 1.46
Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet-derived growth factor-like protein which is secreted. J Cell Physiol (1987) 1.44
Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEM(pUC19) beta-lactamase from Escherichia coli. J Biol Chem (1999) 1.39
Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene. Antimicrob Agents Chemother (1998) 1.38
Beta-lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome. Cell Mol Life Sci (2005) 1.38
Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer (1997) 1.36
Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A (2000) 1.36
Cell-mediated immune response to the recombinant 57-kDa heat-shock protein of Chlamydia trachomatis in women with salpingitis. J Infect Dis (1993) 1.36
Eukaryotic DNA methylation: facts and problems. FEBS Lett (1990) 1.34
Trypsin-sensitive neutralization site on VP1 of Theiler's murine encephalomyelitis viruses. J Virol (1988) 1.31
MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res (2001) 1.28
Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. Antimicrob Agents Chemother (1995) 1.25
Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res (1997) 1.25
Aminoglycoside antibiotics. Structures, functions, and resistance. Adv Exp Med Biol (1998) 1.23
Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J Cell Physiol (1992) 1.23
Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer (1994) 1.22
X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme. J Biol Chem (2001) 1.21
Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Antimicrob Agents Chemother (1994) 1.21
Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases. Cancer Metastasis Rev (1991) 1.20
Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J Cell Physiol (1987) 1.19
Proliferative response to conserved epitopes of the Chlamydia trachomatis and human 60-kilodalton heat-shock proteins by lymphocytes from women with salpingitis. Am J Obstet Gynecol (1994) 1.17
Genetic inactivation of the Serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. J Neurosci (2000) 1.16
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol (2001) 1.16
Purification, characterization, and investigation of the mechanism of aminoglycoside 3'-phosphotransferase type Ia. Biochemistry (1995) 1.15
Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist Updat (2001) 1.15
High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem (1998) 1.15
Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer (1994) 1.14
Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol Psychiatry (2011) 1.11
Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun (1994) 1.11
Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem (2000) 1.11
TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene (2006) 1.09
The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res (1985) 1.06
Purification and characterization of aminoglycoside 3'-phosphotransferase type IIa and kinetic comparison with a new mutant enzyme. Antimicrob Agents Chemother (1994) 1.05
High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res (1996) 1.05
Assessment of Gelatinases (MMP-2 and MMP-9 by Gelatin Zymography. Methods Mol Med (2001) 1.05
Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun (2001) 1.03
Reactions of Escherichia coli TEM beta-lactamase with cephalothin and with C10-dipeptidyl cephalosporin esters. J Biol Chem (1986) 1.03
Detection of Chlamydia trachomatis by the polymerase chain reaction in the cervices of women with acute salpingitis. Am J Obstet Gynecol (1993) 1.03
Structural and mechanistic aspects of evolution of beta-lactamases and penicillin-binding proteins. Curr Pharm Des (1999) 1.03
Cell interaction with the extracellular matrices produced by endothelial cells and fibroblasts. Exp Cell Res (1985) 1.02
Critical hydrogen bonding by serine 235 for cephalosporinase activity of TEM-1 beta-lactamase. Antimicrob Agents Chemother (1993) 1.02
The structure of adenovirus chromatin in infected cells. J Gen Virol (1985) 1.01
Differential structural requirements for the induction of cell attachment, proliferation and differentiation by the extracellular matrix. Exp Cell Res (1985) 1.01
Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res (1999) 1.01
X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Biochemistry (1999) 1.00
The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol (1993) 1.00
The serotonin1A receptor gene as a genetic and prenatal maternal environmental factor in anxiety. Proc Natl Acad Sci U S A (2010) 1.00
In vivo bacterial protease production during Pseudomonas aeruginosa corneal infection. Invest Ophthalmol Vis Sci (1995) 1.00
Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer (2001) 0.99
Class C beta-lactamases operate at the diffusion limit for turnover of their preferred cephalosporin substrates. Antimicrob Agents Chemother (1999) 0.98
6-(hydroxyalkyl)penicillanates as probes for mechanisms of beta-lactamases. J Antibiot (Tokyo) (2000) 0.97